Citizens Financial Group Inc. RI Grows Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Citizens Financial Group Inc. RI boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,321 shares of the biopharmaceutical company’s stock after buying an additional 337 shares during the quarter. Citizens Financial Group Inc. RI’s holdings in Gilead Sciences were worth $530,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. EagleClaw Capital Managment LLC boosted its stake in shares of Gilead Sciences by 3.7% in the third quarter. EagleClaw Capital Managment LLC now owns 9,060 shares of the biopharmaceutical company’s stock worth $760,000 after acquiring an additional 325 shares during the last quarter. Altman Advisors Inc. lifted its holdings in Gilead Sciences by 1.2% in the 3rd quarter. Altman Advisors Inc. now owns 20,875 shares of the biopharmaceutical company’s stock valued at $1,750,000 after purchasing an additional 253 shares in the last quarter. Grandfield & Dodd LLC grew its holdings in shares of Gilead Sciences by 0.7% during the third quarter. Grandfield & Dodd LLC now owns 284,909 shares of the biopharmaceutical company’s stock worth $23,887,000 after buying an additional 1,945 shares in the last quarter. First Horizon Advisors Inc. grew its holdings in shares of Gilead Sciences by 8.0% during the third quarter. First Horizon Advisors Inc. now owns 274,687 shares of the biopharmaceutical company’s stock worth $23,030,000 after buying an additional 20,312 shares in the last quarter. Finally, Commerce Bank lifted its stake in shares of Gilead Sciences by 10.8% in the third quarter. Commerce Bank now owns 72,494 shares of the biopharmaceutical company’s stock worth $6,078,000 after buying an additional 7,055 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Price Performance

Shares of GILD opened at $90.19 on Friday. The company has a market cap of $112.40 billion, a P/E ratio of 1,002.11, a PEG ratio of 2.78 and a beta of 0.17. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.90. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The firm’s 50 day moving average price is $87.43 and its 200 day moving average price is $76.86.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. During the same period last year, the firm earned $2.29 earnings per share. The company’s revenue for the quarter was up 7.0% compared to the same quarter last year. On average, research analysts forecast that Gilead Sciences, Inc. will post 4.38 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be paid a dividend of $0.77 per share. The ex-dividend date is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.42%. Gilead Sciences’s payout ratio is 3,422.22%.

Analyst Upgrades and Downgrades

A number of analysts have commented on GILD shares. Citigroup assumed coverage on shares of Gilead Sciences in a report on Thursday, November 14th. They issued a “buy” rating and a $125.00 price objective for the company. Daiwa America upgraded Gilead Sciences to a “hold” rating in a report on Monday, November 18th. Maxim Group cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Truist Financial lifted their target price on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research note on Friday, November 8th. Finally, Sanford C. Bernstein began coverage on shares of Gilead Sciences in a report on Thursday, October 17th. They set an “outperform” rating and a $105.00 price target for the company. Twelve research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and four have given a strong buy rating to the company’s stock. According to MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $95.41.

Insider Activity at Gilead Sciences

In related news, insider Merdad Parsey sold 25,590 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the transaction, the insider now owns 99,599 shares of the company’s stock, valued at $9,113,308.50. This represents a 20.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the sale, the insider now directly owns 78,127 shares of the company’s stock, valued at $6,545,480.06. This trade represents a 27.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 56,947 shares of company stock valued at $4,968,674 over the last 90 days. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.